Please login to the form below

Not currently logged in
Email:
Password:

Stephen Eck joins Aravive Biologics

He takes up president and CEO positions

Aravive Biologics has appointed Stephen Eck as its new CEO and president at a time when the company is preparing to advance its lead drug candidate Aravive-S6 into human clinical testing.

Eck has served a number of global pharmaceutical companies in senior roles, including Eli Lilly and Pfizer, and most recently at Astellas Pharma as vice president of oncology medical sciences.

He said: “I am very excited to be joining Aravive at this point in the company’s development.

"I look forward to helping Aravive realise the full potential that I believe Gas6/AXL inhibition can bring to the treatment of cancer.”

Eck also serves on the board of directors of Texas-based life sciences company Luminex Corporation, he is a fellow of the American Association for the Advancement of Science and is chairman of the board of directors of the Personalised Medicine Coalition.

Ray Tabibiazar, founding president and CEO of Aravive, said: “Stephen has an impressive track-record of oncology drug and biomarker development at prominent pharmaceutical companies, as well as a close relationship to Houston’s M.D Anderson Cancer Centre as a member of the Advisory Board for their oncology Moonshot Programme.

“We welcome his expertise and leadership to the Aravive team.”

Eck succeeds Ray Tabibiazar who will remain as chairman of the company’s board of directors.

12th May 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics